-+ 0.00%
-+ 0.00%
-+ 0.00%

LILLY'S JAYPIRCA (PIRTOBRUTINIB), THE FIRST-AND-ONLY APPROVED NON-COVALENT BTK INHIBITOR, RECEIVES EXPANDED INDICATION FROM U.S. FDA FOR CERTAIN PATIENTS WITH PREVIOUSLY UNTREATED CLL/SLL

Reuters·10/02/2026 19:05:39

Please log in to view news